Durable Regression of Primary Cutaneous B-Cell Lymphoma Following Fever-inducing Mistletoe Treatment: Two Case Reports

Maurice Orange, MSc, Aija Lace, Maria P. Fonseca, Broder H. von Laue, Dr med, Stefan Geider, Dr med, and Gunver S. Kienle, Dr med

Maurice Orange, Maurice Orange, MSc, is a general practitioner, formerly medical director at Park Attwood Clinic, United Kingdom, and currently senior hospital doctor integrative oncology at the Ita Wegman Klinik, Arlesheim.

Contributor Information.

Corresponding author.

Email: [email protected]

Conflict of Interest The authors declare no competing interests.

Abstract

摘要

RESUMEN

CASE 1: PRIMARY CUTANEOUS FOLLICLE CENTER B-CELL LYMPHOMA

A 51-year-old female presented with 2 lesions on the left lower leg in May 2008 at the oncology department of a large tertiary hospital (Aberdeen Royal Infirmary [ARI]). She had first noticed in the summer of 2007 a lesion in the left upper Achilles region, which increased in size and became red. In autumn 2007, a similar lesion developed over the mid shin of the same leg, and in the weeks leading up to presentation, a couple of much smaller satellite lesions appeared around the anterior lesion.

Histopathology confirmed grade 1 follicular B-cell lymphoma (Figures 1 and ​and2).2). Staging computed tomography (CT) scan (chest, abdomen, pelvis) reported no intraabdominal or pelvic lymphadenopathy but showed one 2.7 × 1.7 inguinal lymph node, which was not biopsied. Stage was pT_2bcN_xM_0.²⁶ Hematology, biochemistry, and trephine bone marrow biopsy were essentially normal. IgH gene rearrangement analysis found clonality, confirming B-cell lymphoma; T-cell receptor (TCR)-β–ve; TCR-γ very weakly polyclonal. Cytogenetics: t(11;14) and t(14;18) translocations were not tested.

Open in a separate window

Figure 1

Cellular lymphoid tumor. The pattern is largely diffuse with focal nodular areas (H&E ×10). Image courtesy of Dr Ghada Bashat, Pathology, Aberdeen Royal Infirmary.

Open in a separate window

Figure 2

Cellular lymphoid tumor. The pattern is largely diffuse with focal nodular areas (H&E ×20). Image courtesy of Dr Ghada Bashat, Pathology, Aberdeen Royal Infirmary.

The patient was generally well; she had no history of injury or infection and no B symptoms, such as fatigue, night sweats, weight loss, or pruritus. She had longstanding assumptive skin lipomas in different areas of the body but had been generally healthy, had a grown daughter, worked as a movement therapist, was a non-smoker, drank no alcohol, took no regular medications, and reported no allergies.

In view of the multicentric lesions, with satellites and possible regional node involvement indicative of advancement, it was recommended she undergo systemic immuno-chemotherapy with 6 cycles of cyclophosphamide, vincristine, and prednisone plus rituximab (R-CVP) and involved-field radiotherapy on completion of the cycles. Although the patient was not opposed to this treatment in principle, she decided to keep it in reserve and improve her immunity with ME treatment first.

On presentation for ME treatment in June 2008, the patient had a posterior lesion in the left proximal Achilles region measuring 5 cm × 4 cm (Figure 3) and an anterior mid shin tumor measuring 4 cm × 2 cm (Figure 4), with a number of surrounding satellites, each < 1.5 cm. The 2 large lesions were raised, red, and warm to the touch. The overlying skin was thinned but intact. There were no signs of deep tissue infiltration; she reported no pain, and no neurological deficits were ascertained. The left leg was well perfused, but there was pitting edema around the lesions and the ankle.

Open in a separate window

Figure 3

Primary cutaneous B-cell lymphoma in July 2008. Posterior lesion left lower leg.

Open in a separate window

Figure 4

Primary cutaneous B-cell lymphoma in July 2008. Anterior lesion left lower leg; surrounding satellites not showing clearly.

Treatment

Treatment with ME (using Abnobaviscum fraxini) comprised a combination of IV, intratumoral (IT), and subcutaneous (SC) applications over 12.3 months and IV and SC application over another 8 months. Details are shown in Table 1. Treatment was subdivided in an induction phase, wherein febrile reactions to ME are elicited, and a postinduction phase. ME treatment was combined with whole-body hyperthermia (WBHT)—a technique to increase core temperature to 39° to 39.5°C for 2 to 5 hours with water-filtered infrared A radiation under controlled conditions. The skin lesions were not directly targeted. She had no other cancer treatments and was not taking any medications.

Table 1

Treatment Schedule (06/02/08–06/08/09) of Patient With PCBCL^a

Month	Day or Interval	ME Dosage (mg) Per Application			WBHT
		IV Treatmentb	IT Treatment	SC Treatment (no. of sessions, if > 1)
Induction phase
0	1	40	—	—
	2	80	—	1
	3	160	1	10
	4	—	4	20
	8	160	10	30
	11	160	20	20
	15	160	—	40
Post-induction phase
	16	—	40	40
	18	160	—	—
	21–28c	—	—	(3 ×) 40
	25	200	—	—
1	29–35	—	—	(2 ×) 40
	32	200	—	—
	36–42	—	—	40
	36	200	80	—
	37	—	40	—	No. 1
	42	200	120	—	No. 2
	43–49	—	—	(2 ×) 40
	46	200	—	—
	50–56	—	—	(2 ×) 40
	53	200	—	80
2	57	—	240d	—
	58	200	—	—	No. 3
	61	—	—	—
	64–70	—	—	(2 ×) 40
	67	200	320d	—
	71–77	—	—	(2 ×) 40
	74	200	—	—
	78	—	320d	40
	79	200	—	—	No. 4
3	85–91	—	—	40
	88	200	320d	—
	92–98	—	—	(2 ×) 40
	95	200	—	—
	99	—	320d	—
	100	200	—	—	No. 5
	103–112	—	—	(2 ×) 40
	109	200	—	—
	113–119	—	—	(2 ×) 40
	116	200	—	—
4	120	—	320d	20
	127–140	—	—	(4 ×) 40
	135	200	—	—	No. 7
5	141–161	—	—	(5 ×) 40
	162	—	360d	—
	163	200	—	—	No. 8
6	169–182	—	—	(3 ×) 40
	178	200	—	—
	183–189	—	—	(2 ×) 40
	190	—	400d	—
	Best Ways to Pass a Hair Follicle Drug Test for Weed Best Detox Drinks to Pass Urine Drug Test Stinger Detox Review 191	200	—	—	No. 9
	197–210	—	—	(4 ×) 40
	204	200	—	—
	211–231	—	—	(6 ×) 40
	233	—	400d	—
	234	200	—	—	No. 10
	237–271	—	—	(12 ×) 20
	254	200	—	—
	272	—	400d	—
	279–369	—	—	(13 ×) 40
	338	200	—	—
12	370	—	240d	—
	371	200	—	—	No. 12
	372	End of IT treatment; subsequent IV and SC treatment and WBHT not shown.
Total
No. of applications		33	19	81	12 ×
ME dosage		6120	3950	2901

Open in a separate window

Abbreviations: IT, intratumoral; IV, intravenous; ME, mistletoe extract; PCBCL, primary cutaneous B-cell lymphoma; SC, subcutaneous; WBHT, whole-body hyperthermia.

^aMonth and day (interval) of treatment; mode, dose, and number of ME applications; application of WBHT.

^bInfused in 250 mL sodium chloride 0.9%, over 60–90 minutes.

^cTreatment periods of 1 or more weeks during which SC injections were given.

^dIT distributed over both lesions.

During induction, the patient had 4 febrile responses of ≥38.5°C lasting < 24 hours with maximum readings of 38.5°C (after day 3); 38.7°C (after day 4); 39.1°C (after day 8); and 38.6°C (after day 11). For the IT approach, the lesions were injected from the healthy skin margins to avoid breaking the paper-thin skin overlying the bulging tumors. The volume of ME fluid often exceeded 20 mL (20 mg/mL/ampoule) and was injected evenly intraand perilesional while repositioning the needle during injection.

After IT treatment, the lesions responded with immediate postinjection swelling and inflammation, followed by clinical resolution of inflammation, and over the course of treatment, the lesions successively appeared less inflamed. The rate of regression seemed slightly accelerated after starting WBHT (day 37), and after 4 months, there was a clear overall improvement. The lesions continued to show injection-associated fluctuations, and the posterior lesion resolved first.

The lesions steadily decreased in volume, consistency, and redness. The remission was assessed by visual inspection and palpation and confirmed by 3 independent clinicians from 3 different clinical settings, including the ARI. The overall fitness and stamina of the patient improved. Re-scanning in May 2009 reflected “No significant supraclavicular, axillary or mediastinal … retroperitoneal or pelvic lymphadenopathy; as before, there are inguinal nodes the largest of which is on the left and measuring 1.3 × 1.8 cm. This node was documented as 2.7 × 1.7 cm on staging.” Routine full blood count and biochemistry were normal. Given the favorable clinical signs of control, the IT injections were discontinued at 12.3 months. Combined IV and SC ME treatment with WBHT continued for another 8 months, and the lesions continued to regress. The areas blanched eventually, leaving depressed (posterior, Figure 5) and level (anterior lesion, Figure 6) hyperpigmented areas. Conventional therapy was deferred indefinitely. At last review in December 2011, the patient was doing well and remained in remission; the appearances were similar to those from June 2011 (Figures 7 and ​and88).

Open in a separate window

Figure 5

Primary cutaneous B-cell lymphoma in May 2010. Posterior left lower leg; posttreatment pigmentation and depression.

Open in a separate window

Figure 6

Primary cutaneous B-cell lymphoma in May 2010. Anterior left lower leg showing pigmentation changes.

Open in a separate window

Figure 7

Primary cutaneous B-cell lymphoma in June 2011. Posterior left lower leg.

Open in a separate window

Figure 8

Primary cutaneous B-cell lymphoma in June 2011. Anterior left lower leg.

CASE 2: PRIMARY CUTANEOUS MARGINAL ZONE B-CELL LYMPHOMA

A 52-year-old flight attendant was diagnosed at the same oncology department (ARI) with stage 2A, pT_2ac-N_xM₀ primary cutaneous marginal zone B-cell lymphoma (PCMZL). In December 2007, 2 to 3 days after venapunction, he developed a lesion in the left antecubital fossa, which was excised in May 2008. The histopathology showed nodal marginal zone lymphoma (Figure 9). A staging CT scan of the neck, chest, abdomen, and pelvis showed no signs of systemic disease; trephine bone marrow biopsy, biochemistry, and hematology were normal. Shortly after excision, the patient developed a second lesion on the right anterior chest wall, medial to the right anterior axillary fold. The lesion was only palpable (no photographs). The patient was asymptomatic, had no recent weight loss or fatigue. Several treatment options were recommended: R-CVP, 10 fractions of involved-field radiotherapy of the 2 sites, or 6 months’ pulsed chlorambucil; he declined these options.

Open in a separate window

Figure 9

Nodular marginal zone lymphoma. The architecture of the node is diffusely effaced by a population of lymphoid, plasmacytic, and histiocytic cells (H&E ×10). Image courtesy of Dr Ghada Bashat, Pathology, Aberdeen Royal Infirmary.

The patient had a history of rosacea with keratitis; actinic keratoses of upper back (treated with occasional cryotherapy); 2 basal cell carcinomas—one of the upper back (excised 1999) and one of the left leg (excised early 2007)—and an uncertain diagnosis of facial cutaneous scleroderma with no visceral involvement, but raised titres of antinuclear factor, which was unresponsive to azathioprine and oral prednisolone (2004). He used nicotine and alcohol moderately. Apart from emollients, he used no other regular conventional medications, reported no formal allergies, and was mistletoe-naïve. He had had no recent infections and no soft tissue trauma.

On presentation at PAC in August 2008, the patient was in good general health, with a Karnofsky Performance Scale status of > 90%. There was one soft and mobile lymph node in the left axilla. The right upper thoracic lesion was 2 × 3 cm palpable and mobile. There were no other abnormal findings.

DISCUSSION

The primary cutaneous B-cell lymphoma of 2 patients regressed after administration of a combination of SC, IV, and IT applications of high-dose, fever-inducing ME treatment. The rationale for the combination was to optimize immune responses as currently understood to elicit fever and to apply the principle of “in situ” vaccination with IT application. In one patient, WBHT was added to draw on the benefits of improved immune competence that is associated with fever-range hyperthermia.²⁹ Three and a half years since commencement, the patients remain in clinical remission.

With high dosage, especially local ME applications, tumor remissions have been reported repeatedly in a number of tumor types, including breast cancer, Merkel cell cancer, primary liver cancer, pancreatic cancer, and cutaneous squamous cell cancer.^25–27 Still, high-dose and combined IT, IV, and SC administration that aims to elicit febrile induction is uncommon and underreported.

The literature on ME treatment of lymphoma is limited compared to that of other tumor types. One retrospective study describes favorable outcomes, including a few remissions in a group of 61 patients with follicular non-Hodgkin’s lymphoma treated with a lowlectin ME (Iscador Pini) either alone or combined with or on completion of chemotherapy.³⁰ Another retrospective study primarily investigated safety aspects of ME treatment in Hodgkin’s and non-Hodgkin’s lymphoma and found no risks.³¹ Some case reports describe remission of non-Hodgkin’s lymphoma under ME monotherapy,^32–35 including 2 in cutaneous T-cell lymphoma in children.^36,37 In these cases, the dosage was lower than in the cases reported here and applied mainly subcutaneously and only partly intravenously and intratumorally. At least one fever reaction was reported.

Preclinical studies with lymphoma cells and murine lymphoma models treated with ME, isolated MLs, recombinant ML, and other ME peptides have consistently shown antitumoral effects with tumor inhibition, inhibition of metastases, and survival benefit.^19,38–42 ME contain several cytotoxic ingredients, among them lectins and viscotoxins, which are particularly abundant in Abnobaviscum fraxini. When lec-tins are applied systemically, their cytotoxicity is moderated by serum proteins⁴³ and later by the occur-rence of anti-ML antibodies;⁴⁴ hence, their cytotoxicity is to be expected, primarily with IT administration. However, a disease response could also be effected by an immunological mechanism, as has been demonstrated for ME repeatedly.^19,20 Furthermore, fever seems to have a role in tumor defense.⁴⁵ The impact of ME treatment cannot be easily ascertained when used concurrently with mainstream cancer therapy. Occasionally, however, patients postpone or decline recommended conventional treatment in favor of ME, and such cases allow evaluation of ME treatment alone. Two of these patients are described above; these are the only two cutaneous lymphoma cases treated at PAC with ME alone and are therefore unselected. The cases of 2 other patients from PAC who had cancer at other sites and were treated with ME monotherapy have been published previously.²⁷

In lymphoma, spontaneous remission is estimated to occur in 5% to 20% of cases. It is sometimes of long duration^16,17,46,47 and often is associated with reducing an immunosuppressive treatment or condition; following fever, viral or bacterial infections, or vaccination; or after biopsy and following eradication of helicobacter in gastric lymphoma.¹⁷ In a small follow-up study observing patients over many years, spontaneous remissions were reported in 4 of 16 patients with PCFCL (one of them complete) and in 4 of 8 patients with PCMZL (none of them complete), all of whom had a relapse.⁴⁸ Although spontaneous remission could have played a role in the cases presented here, in the first of the cases presented, the lesions had grown progressively until commencement of ME treatment and then steadily decreased, with fluctuating treatment-related inflammatory responses. In the second case, the lesion resolved after initial treatment-related increase and with some delay, which is a known response pattern in ME-associated tumor remissions.^26,30 Therefore, a mere coincidence is unlikely, especially as the 2 cases are unselected (meaning that they were not selected from a larger group of patients with cutaneous lymphomas treated with ME but were the only patients with cutaneous lymphonas treated in this way) and represent the only patients with PCBCL from PAC that had been treated with ME monotherapy. One also has to consider that the fever-induction ME treatment is likely to upregulate just those mechanisms implicated in the frequent spontaneous remission described for lymphoma.

Two further case publications on ME treatment of a related entity, CD30+ T-cell lympho-proliferation, reported complete regression of multiple and active cutaneous and nodal disease.^37,38 In one case, treatment consisted of low-dose IV (3 infusions of 0.02 mg, 0.2 mg, and 2 mg) and SC (up to 2 mg twice a week) without fever or site responses, with a noticeable disease response within 1 week and durable (30 months) complete response (CR) within 4 weeks. The second case was treated with primary fever intent (38°C), IT, and SC, and had a dose-dependent partial response and CR that relapsed with a lower-dose ME but regressed again with dose increase.

A differentiated appreciation of the singular components of the combined ME treatment—the specific role of fever and each of the specific contributions of SC, IT, and IV—and of the synergies is not possible given the current knowledge and require further research.

Although treatment was well tolerated and the safety observed is in accordance with other investigations on the safety of ME treatment in higher dosage,²⁸ this treatment should be reserved for use by physicians who have experience with ME application in higher dosages and IT/IV until further investigations have explored the role of high-dose, fever-inducing ME in cancer and its safety in more detail.

CONCLUSION

High-dose, fever-inducing mistletoe treatment seems to have beneficial effects in two cases of primary cutaneous B-cell lymphoma. Further research is needed to investigate antitumor effects, potential mechanisms of action, best mode of application, and the associated safety and efficacy.

Contributor Information

Maurice Orange, Maurice Orange, MSc, is a general practitioner, formerly medical director at Park Attwood Clinic, United Kingdom, and currently senior hospital doctor integrative oncology at the Ita Wegman Klinik, Arlesheim.

Maria P. Fonseca, Maria P. Fonseca was formerly an assistant general practitioner at Park Attwood Clinic and currently is in private practice at Emerson College, United Kingdom.

Broder H. von Laue, Broder H. von Laue, Dr med, is senior doctor, oncology focused practice, Niefern-Oeschelbronn, Germany.

Stefan Geider, Stefan Geider, Dr med, is a general practitioner at Camphill Medical Practice NHS, St John’s, Aberdeen, United Kingdom.

Gunver S. Kienle, Gunver S. Kienle, Dr med, is senior research scientist at the Institute for Applied Epistemology and Medical Methodology at the University of Witten/Herdecke in Freiburg, Germany.

REFERENCES